• 中文简体
  • 中文繁体
  • English
  • العربية
  • ABOUT IASO
    Company OverviewManagement TeamScientific Advisory BoardPartnership
  • SCIENCE & PRODUCTS
    PipelineTechnology PlatformsManufacturingPublictaionsExpanded Access
  • NEWS
    Press ReleaseMedia Report
  • CAREERS
    Working at IASOOpportunities
  • CONTACT

Focusing on innovative
biotherapies to bring
hope of cure to patients

We aspire to bring new and curative 

treatment in the fields of hematologic  

malignancies and autoimmune

diseases

Integrated capabilities cross discovery and development to manufacturing and commercialization.

  • Pipeline

    Diversified and balanced pipeline developed with a forward-looking, de-risked development approach.

  • Technology platform

    Our leading and intergrated platforms leverage advanced technologies that span the entire product lifecycle.

  • Manufacturing

    A mature and stable CMC platform enabling large-scale, high-quality manufacturing.

News

11/112026

IASO Bio Announces NMPA IND Approval for IASO208, Advancing Its In Vivo CAR-T Platform into Synchronized U.S.–China Clinical Development

10/112026

IASO Bio Announces Early Clinical Data from Investigator-Initiated Trial of Equecabtagene Autoleucel Injection in Patients with Refractory Lupus Nephritis at ACR Convergence 2026

05/112026

Expanding into Non-Oncology: IASO Biotechnology and Longuide Biopharma Announce LNP Collaboration

More
  • ABOUT IASO
  • SCIENCE & PRODUCTS
  • NEWS
  • CAREERS
  • CONTACT
Copyright © 2023 南京驯鹿生物技术股份有限公司
苏ICP备2021047135号
Privacy Policy | Terms of Use

WeChat
LinkedIn
i-connection